Antiepileptické léky a lékové interakce: klinická kazuistika
Authors:
Hundie Tesfaye 1; E. Eva Klapková 1; Alena Tesfayeová 2; Vladimír Komárek 2
Authors‘ workplace:
Department of Clinical Biochemistry and Pathobiochemistry, Division of Clinical Pharmacology, University Hospital, Motol, nd Faculty of Medicine, Charles University, Prague, Czech Republic
1; Department of Paediatric Neurology, University Hospital, Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
2
Published in:
Čas. Lék. čes. 2011; 150: 451-456
Category:
Case Report
Overview
Epilepsie je závažné onemocnění postihující dětskou i dospělou část populace po celém světě. Vzhledem k btížnému zjišťování etiologie je prvotní nastavení léčebných postupů často řízené empirickými terapeutickými úvahami. Zvládnutí projevů vyžaduje použití antiepileptických léčiv, přičemž mnoho z ich vykazuje možné lékové interakce. Speciálně děti jsou vnímavé k ékovým interakcím a často vykazují atypické nežádoucí projevy vyžadující speciální péči.
Cíl.
Popis případu patnáctileté dívky trpící refrakterní epilepsií na podkladě fokální kortikální dysplazie, u níž bylo zhoršování klinického stavu s elkou pravděpodobností spojováno s ékovými interakcemi mezi běžně předepisovanými antiepileptiky, jmenovitě kyselinou valproovou, fenobarbitalem, nebo primidonem a karbamazepinem.
Klíčová slova:
fokální kortikální dysplazie, léky na refrakterní epilepsii, léková interakce.
Sources
1. Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002; 125: 22–31.
2. Reynolds EH, Rodin E. The clinical concept of epilepsy. Epilepsia 2009; 50(Suppl 3): 2–7.
3. Meencke HJ. Clinical neuropathology of the epilepsies in the 100 years of the ILAE (1909–2009). Epilepsia 2009; 50 (Suppl 3): 8–16.
4. Manon-Espaillat R, Burnstine TH, Remler B, et al. Antiepileptic drug intoxication: factors and their significance. Epilepsia 1991; 32: 96–100.
5. Bourgeois BF. New antiepileptic drugs in children: which ones for which seizures. Clin Neuropharmacol 2000; 23: 119–132.
6. Novak PH, Ekins-Daukes S, Simpson CR, Milne RM, Helms P, McLay JS. Acute drug prescribing to children on chronic antiepilepsy therapy and the potential for adverse drug interactions in primary care. Br J Clin Pharmacol 2005; 59: 712–717.
7. Clarkson I, Choonara I. Surveillance for fatal suspected adverse drug reactions in the UK. Arch Dis Child 2002; 87: 462–467.
8. Aycicek A, Iscan A. The effects of carbamazepine, valproic acid and phenobarbital on the oxidative and antioxidative balance in epileptic children Eur Neurol 2007; 57: 65–69.
9. Mehndiratta MM, Mehndiratta P, Phul P, Garg S.Valproate induced non hepatic hyperammonaemic encephalopathy (VNHE) – a study from tertiary care referral university hospital, north India. J Pak Med Assoc 2008; 58: 627–631.
10. Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J. Valproate-induced hyperammonemic encephalopathy. Acta Neurol Scand 2006; 114: 1–7.
11. Wadzinski J, Franks R, Roane D, Bayard M. Valproate-associated hyperammonemic encephalopathy. J Am Board Fam Med 2007; 20: 499–502.
12. Balla J. “Dilantin” overdose Med J Aust 1968; 2: 480–481.
13. Eadie MJ, Sutherland JM, Tyrer JH. “Dilantin” overdosage. Med J Aust 1968; 2: 515.
14. Tyrer JH, Eadie MJ, Sutherland JM, Hooper WD. Outbreak of anticonvulsant intoxication in an Australian city. BMJ 1970; 4: 271–273.
15. Burkhardt RT, Leppik IE, Blesi K, Scott S, Gapany SR, Cloyd JC. Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Neurology 2004; 63: 1494–1496.
16. Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, Haskins LS. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology 2008; 71: 525–530.
17. Nielsen KA, Dahl M, TŅmmerup E, Wolf P. Comparative daily profiles with different preparations of lamotrigine: a pilot investigation. Epilepsy Behav 2008; 13: 127–130.
18. Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 2007; 48: 464–469.
19. LeLorier J, Duh MS, Paradis PE, Lefebvre P, Weiner J, Manjunath R, Sheehy O. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology 2008; 70(22 Pt 2): 2179–2186
20. Zachry WM 3rd, Doan QD, Clewell JD, Smith BJ. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia 2009; 50: 493–500.
21. Frank EL, Schwarz EL, Juenke J, Annesley TM, Roberts WL. Performance characteristics of four immunoassays for antiepileptic drugs on the IMMULITE 2000 automated analyzer. Am J Clin Pathol 2002; 118: 124–131.
22. Matos ME, Burns MM, Shannon MW. False-positive tricyclic antidepressant drug screen results leading to the diagnosis of carbamazepine intoxication. Pediatrics 2000; 105(5): E66.
23. Dasgupta A, McNeese C, Wells A. Interference of carbamazepine and carbamazepine 10,11-epoxide in the fluorescence polarization immunoassay for tricyclic antidepressants: estimation of the true tricyclic antidepressant concentration in the presence of carbamazepine using a mathematical model. Am J Clin Pathol 2004; 121: 418–425.
24. Mayer T, May TW, Alternmüller DM, Sandmann M, Wolf P. Clinical problems with generic antiepileptic drugs. Clin Drug Invest 1999; 18: 17–26.
25. McEvoy GK. (ed.) American hospital formulary service, drug information. Bethesda, MD: American Society of Hospitál Pharmacists 1991; 1147.
26. Reynolds JEF (ed.) Martindale, the extra pharmacopoeia, 29th ed. London: The Pharmaceutical Press 1989; 413.
27. Ambrósio AF, Soares-Da-Silva P, Carvalho CM, Carvalho AP. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res 2002; 27: 121–130.
28. Reynolds NC Jr, Murthy VS. Serum free levels and evaluation anticonvulsant drug interactions. Wis Med J 1989; 88: 25–27.
29. Ju C, Uetrecht JP. Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate. J Pharmacol Exp Ther 1999; 288: 51–56.
30. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 1988; 82: 1826–1832.
31. Riley RJ, Kitteringham NR, Park BK. Structural requirements for bioactivation of anticonvulsants to cytotoxic metabolites in vitro. Br J Clin Pharmacol 1989; 28: 482–487.
32. Luo G, Cunningham M, Kim S, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002; 30: 795–804.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
Most read in this issue
- Současné možnosti léčení poranění pánevního kruhu
- Klinický význam nemoci spojené s imunoglobuliny IgG4
- Reaktivní kyslíkové a dusíkové sloučeniny v klinické medicíně
- Nejčastěji využívané metodiky k analýze DNA metylačních změn